Small fiber neuropathy (SFN) is a condition where the smallest nerve fibers in your body become damaged or die off, causing burning pain, tingling, and a range of autonomic problems like abnormal sweating or digestive issues. Unlike more common forms of neuropathy that show up on standard nerve conduction tests, SFN specifically targets the thinnest nerve fibers, which makes it harder to diagnose and easy to miss. About half of all cases have no identifiable cause.
Which Nerves Are Affected
Your nervous system contains different sizes of nerve fibers, and SFN targets the two smallest types. The first are thinly insulated fibers called A-delta fibers, which carry sharp pain and temperature signals at moderate speeds. The second are C-fibers, which have no insulation at all and transmit dull, burning pain, warmth, and itch sensations much more slowly. These same C-fibers also control a wide range of automatic body functions: heart rate regulation, sweating, digestion, bladder control, and blood vessel tone.
The damage in SFN appears to come from the nerve endings dying back, starting at the tips farthest from the spinal cord (usually in the feet) and gradually working inward. Researchers believe this degeneration involves reduced blood flow to the nerve fibers, inflammation, and oxidative stress, though the exact chain of events is still not fully mapped out. Because the damage targets such tiny fibers, the larger nerves responsible for muscle strength and reflexes remain intact, at least early on.
What It Feels Like
The hallmark of SFN is pain that seems out of proportion to any visible injury. People commonly describe burning, stinging, or electric shock sensations in their feet, and sometimes their hands. Some experience allodynia, where normally painless contact like bed sheets touching the feet becomes painful. Others notice reduced ability to sense temperature, which can make it hard to tell if bathwater is dangerously hot.
The autonomic symptoms are often the most disruptive and the least recognized. These can include:
- Sweating abnormalities: patches of excessive sweating or areas where sweating stops entirely
- Cardiovascular changes: lightheadedness on standing, rapid heart rate, or blood pressure swings
- Digestive problems: bloating, constipation, diarrhea, or early fullness after eating
- Bladder and sexual dysfunction
- Dry eyes and dry mouth
Most people notice symptoms in the feet first, following a “length-dependent” pattern where the longest nerves degenerate earliest. But some develop a “non-length-dependent” pattern, with patchy pain or burning that can appear on the torso, face, or arms without following that typical feet-first progression.
Common Causes
In roughly 53% of SFN cases, no underlying cause is ever identified. For the rest, diabetes and prediabetes are the most frequent triggers. Chronically elevated blood sugar damages small nerve fibers through a combination of metabolic stress and reduced blood flow. Autoimmune conditions, including Sjögren’s syndrome, lupus, celiac disease, and sarcoidosis, account for another significant portion.
Genetics play a larger role than previously thought. Mutations in genes that control sodium channels on pain-sensing nerves have been found in a meaningful number of people with unexplained SFN. About 30% of patients with idiopathic SFN carry a mutation in one specific sodium channel gene (SCN9A). A broader study of over 1,100 patients with pure SFN found that 11.6% had mutations across three related sodium channel genes. These mutations can make pain-sensing nerves fire too easily or too often, contributing directly to the burning pain that defines the condition.
Other known causes include excessive alcohol use, certain chemotherapy drugs, HIV, vitamin B12 deficiency, thyroid disorders, and hepatitis C.
How SFN Is Diagnosed
One of the most frustrating aspects of SFN is that standard nerve conduction studies come back normal. Those tests measure electrical signals in large nerve fibers, and small fibers are simply too thin to register. A normal result does not rule out SFN.
The most established diagnostic tool is a skin punch biopsy, typically taken from the lower leg near the ankle and sometimes the upper thigh. A pathologist counts the number of nerve fiber endings that penetrate the outer layer of skin, called the intraepidermal nerve fiber density (IENFD). If that count falls below age- and sex-adjusted norms, it confirms small fiber damage. The biopsy itself is straightforward: a tiny 3mm sample of skin removed under local anesthetic, requiring no stitches.
That said, skin biopsy is not perfect. One comparative study found it had a sensitivity of only 58%, meaning it misses a substantial number of people who truly have SFN, though its specificity was high at 92%, so a positive result is quite reliable. Quantitative sensory testing (QST), which measures your ability to detect warm, cool, and vibration stimuli on the feet, is often used alongside biopsy. Sweat function testing evaluates autonomic small fibers but has lower accuracy on its own, with sensitivity of 53% and specificity of 69% in one head-to-head comparison.
The current diagnostic framework grades SFN as possible (symptoms alone), probable (clinical signs plus normal standard nerve tests), or definite (clinical signs, normal standard nerve tests, and an abnormal biopsy or sensory threshold test). In practice, many neurologists combine multiple tests to build a complete picture. A newer option, corneal confocal microscopy, uses a specialized eye scanner to image the tiny nerve fibers in the cornea. It’s noninvasive, repeatable, and can be done quickly. When added to skin biopsy results, it helped identify small fiber damage in 85% of patients with idiopathic SFN in one detailed study, compared to 70% with biopsy alone. It also allows doctors to track changes over time without repeated biopsies.
Treatment and Pain Management
The first priority is treating whatever underlying condition is driving the nerve damage. For people with diabetes or prediabetes, tighter blood sugar control can slow or sometimes halt progression. For autoimmune causes, treating the immune dysfunction may allow some nerve fiber regrowth. When celiac disease is the trigger, a strict gluten-free diet led to subjective improvement in 64% of patients in one trial, with measurable nerve function gains over a year.
For pain management, medications that calm overactive nerve signaling are the standard approach. These fall into a few main categories. Antidepressants that boost both serotonin and norepinephrine are generally considered first-line options, as are anticonvulsant medications that dampen nerve excitability. With some of these drugs, pain relief at the starting dose may take several weeks to become apparent, while others can show benefit within days. Treatment typically starts at the lowest dose and increases gradually based on pain relief and side effects like drowsiness or dizziness.
Topical treatments applied directly to painful areas are a practical option, particularly for older adults who may be more sensitive to the systemic side effects of oral medications. These creams or patches deliver pain relief locally and carry a much lower risk of drowsiness or cognitive effects.
Diet and Lifestyle Factors
Growing evidence supports dietary changes as a meaningful complement to medical treatment. A trial of people with type 2 diabetes and peripheral neuropathy found that a low-fat, plant-based diet supplemented with vitamin B12 significantly reduced both pain severity and overall neuropathy severity compared to a control group, with measurable improvement in nerve function in the feet. Plant-based, Mediterranean, and Nordic dietary patterns rich in whole grains, vegetables, legumes, nuts, and olive oil appear to reduce oxidative stress and neuroinflammation, two of the processes believed to drive small fiber degeneration.
Calorie reduction alone may also help. A 30-day low-calorie diet in patients with chronic nerve pain produced significant reductions in both the sensory and emotional dimensions of pain. While these studies weren’t all specific to SFN, the underlying mechanisms of nerve pain overlap considerably, and anti-inflammatory diets address the same pathways involved in small fiber damage.
Long-Term Outlook
SFN tends to progress slowly. Symptoms often worsen over a period of time and then plateau, sometimes remaining stable for years. The condition is not life-threatening, but the chronic pain and autonomic symptoms can significantly affect quality of life, sleep, and mental health.
One important consideration is the risk of progression to large fiber neuropathy, which affects the nerves responsible for vibration sense, touch, balance, and coordination. Studies estimate that between 13% and 36% of people with SFN eventually develop large fiber involvement. This can feel like wearing thick gloves or socks, with numbness replacing or joining the burning pain, and it may affect balance and increase fall risk. Regular follow-up with nerve testing can catch this transition early.